REVIEW article
Front. Microbiol.
Sec. Infectious Agents and Disease
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1637254
This article is part of the Research TopicMechanisms and Innovations in Combating Intracellular InfectionsView all 5 articles
Progress of anti-tuberculosis drug targets and novel therapeutic strategies
Provisionally accepted
Yang Zhang1
Ruiying Wu1
Mingrui Sun1
Xiaotian Li1
Ren Fang1
Jiayin Xing1
Zhaoli Li2*
Yurong Wen3*
Ningning Song1*- 1Shandong Second Medical University, Weifang, China
- 2SAFE Pharmaceutical Technology Co., Ltd., Beijing, China
- 3The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Tuberculosis, a chronic infectious disease caused by Mycobacterium tuberculosis complex, has re-emerged as the leading cause of death worldwide as a single infectious agent. The increasing prevalence of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis poses a severe and growing threat to global health. Therefore, it is urgent to find new drug targets. Recently, significant advancements have been made in the research of drug targets and novel therapeutic strategies for tuberculosis. This review summarizes recent processes on anti-tuberculosis drug targets, such as cell wall synthesis, nucleic acid replication and transcription, energy metabolism, and ferroptosis. Furthermore, this review summarizes the research progress of three innovative tuberculosis treatment strategies, including antimicrobial peptides, host-directed therapies, and nanoparticle-based drug delivery systems, aiming to provide a theoretical foundation and new research perspectives for the clinical development of new drugs.
Keywords: Anti-tuberculosis drugs, Tuberculosis treatment, Mycobacterium tuberculosis, Drugtarget, novel therapeutics
Received: 29 May 2025; Accepted: 21 Aug 2025.
Copyright: © 2025 Zhang, Wu, Sun, Li, Fang, Xing, Li, Wen and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhaoli Li, SAFE Pharmaceutical Technology Co., Ltd., Beijing, China
Yurong Wen, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Ningning Song, Shandong Second Medical University, Weifang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.